GS 4104 neuraminidase inhibitor: Phase III

GILD partner F. Hoffmann-La Roche Ltd. presented data from a U.S. Phase III treatment study of GS 4104 in 629 patients, showing a 30 percent reduction in illness. Median disease duration was 2.9 days in both the 75 mg (p=0.0001) and 150 mg (p=0.001) GS 4104 groups versus 4.3 days in the placebo group (see Technology Briefing, BioCentury Part I). Secondary influenza complications, primarily bronchitis and sinusitis, occurred in 18 percent of patients receiving placebo compared with 10 percent in the 75 mg group (p=0.017) and 7 percent of the 150 mg group (p=0.017).

The proportion of patients with fever after 36 hours was reduced by 60 percent and severity and duration of cough was reduced by 35 percent in the active dose arms. ...